Opthea to Showcase AMD Therapy Breakthroughs

Opthea Limited (AU:OPT) has released an update.

Opthea Limited, a biopharmaceutical firm, will present their advancements in treating wet AMD with their leading candidate, sozinibercept, at the Innovate Retina Meeting. Dr. David Boyer will discuss the Phase 2b trial results and the ongoing Phase 3 trials aimed at improving treatment efficacy over standard therapies. The company is focused on addressing the significant unmet needs in retinal diseases like wet AMD and diabetic macular edema.

For further insights into AU:OPT stock, check out TipRanks’ Stock Analysis page.